No Data
Hong Kong stock Concept tracking | BEIGENE has become the domestic "leader in Innovative Drugs". Institutions are Bullish on the valuation recovery of Innovative Drugs in 2025 (with associated Concept stocks).
On February 21, BEIGENE surpassed Jiangsu Hengrui Pharmaceuticals with a market cap difference of 2.7 billion yuan, becoming the "big brother of innovative drugs."
China International Capital Corporation: Maintaining AKESO (09926) "Outperform Industry" rating with a Target Price of 90 HKD.
It is recommended to pay attention to the domestic and international data readout and sales progress of Kangfang and Summit.
[Brokerage Focus] BOCOM INTL maintains a Buy rating for AKESO (09926), as the potential of PD-1 bispecific antibody combined with ADC is worth anticipating.
Gold News | BOCOM INTL's Research Reports indicate that AKESO (09926) will conduct clinical trials for combination therapies using the ADCs with Pfizer: On February 24, Summit Therapeutics announced the establishment of a clinical trial collaboration with Pfizer to jointly promote the application of PD1/VEGF dual antibody in combination with several vedotin ADCs from Pfizer in various solid tumors. The relevant clinical trials are expected to start in mid-2023, with Summit primarily focusing on phase Ib/II trials initially. Pfizer will be fully responsible for the clinical trials.
BOCOM INTL: There is significant room for recovery in the mainland pharmaceutical Sector, and the foreign investment environment is expected to improve.
Subsequent bullish policies for finance and medical insurance/commercial insurance are expected to continue to be introduced, and the overall valuation of the sector remains at a historical low, indicating significant room for recovery in the sector, thus giving the mainland pharmaceutical Industry a "leading" rating.
Akeso's Partner Summit, Pfizer Collaborate To Evaluate Ivonescimab In Solid Tumor Settings
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
MayFlower : It was predictable..
Midnite52 : yep